98%
921
2 minutes
20
Background: The clinical outcomes of comparing covered stents (CSs) and drug-coated balloons (DCBs) angioplasty in femoropopliteal artery occlusion remain unknown. This study aimed to evaluate the midterm efficacy of CS and DCB procedures in patients with FPO.
Methods: All 194 patients were divided into CS (94 patients) and DCB (100 patients) groups in this multicenter retrospective study. The primary end point was primary patency at 24 months, and the secondary end points included freedom from clinically driven target lesion revascularization, limb salvage, major adverse events, and overall survival rates. Propensity score matching analysis was performed to reconfirm the main end points.
Results: Compared with the patients in the DCB group, those in the CS group had a lower prevalence of smoking (54.3% versus 74.0%, =0.004) and diabetes (38.3% versus 66.0%, <0.001) before propensity score matching. Compared with the DCB procedure, the CS procedure resulted in a significantly greater primary patency at 24 months (74.4% versus 55.8%, =0.019), with comparable primary patency at 12 months; similar results were obtained after matching. However, there was no difference in terms of clinically driven target lesion revascularization, limb salvage, major adverse events, or overall survival rates. Subgroup analyses confirmed the superior clinical patency of CS in patients with diabetes (=0.010) and proximal reference vessel diameter ≥5.0 mm (=0.038). A baseline ankle brachial index <0.40 was likely to be an independent risk factor for restenosis, and a postprocedural ankle brachial index ≥0.80 and the CS used (hazard ratio [HR], 0.54 [95% CI, 0.32-0.91], =0.021) were potential protective factors for restenosis after multivariate analysis.
Conclusions: Compared with the DCB procedure, the CS procedure resulted in greater primary patency at 24 months in complicated femoropopliteal artery occlusion lesions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/JAHA.124.039384 | DOI Listing |
J Pediatr Surg
September 2025
Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, Santa Cecília, 90035-003, Porto Alegre, Rs, Brazil; Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2400, Santa Cecília, 90035-003, Porto Alegre, RS, Brazil.
Background: Obstructions of the tracheobronchial tree can result from various etiologies. Most cases of tracheal stenosis or tracheomalacia are associated with patient-specific anatomical and functional abnormalities, making treatment challenging. Despite progress in the development of tracheal support devices, the optimal or near-optimal stent design remains elusive.
View Article and Find Full Text PDFEndoscopy
December 2025
Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Vasa
September 2025
FIFOS - Forum for Integrative Research & Systems Biology, Vienna, Austria.
Endovascular therapy has emerged as an effective minimally invasive approach for treating peripheral artery disease (PAD). Postprocedural dual antiplatelet therapy (DAPT) is commonly used to prevent adverse events, but optimal management remains uncertain. This international, multicentre retrospective study synthesized data from three studies on covered stents (VIABAHN Endoprosthesis) in 437 PAD patients (2001-2015).
View Article and Find Full Text PDFAnn Med Surg (Lond)
September 2025
Internal Medicine Department, Chirayu National Hospital and Medical Institute (CNHMI), Maharajgunj, Kathmandu, Nepal.
Introduction: Laparoscopic cholecystectomy (LC) is the gold standard for gallbladder pathologies, but carries risks of bile duct injury (BDI) and vascular complications, such as hepatic artery pseudoaneurysm (HAP). While BDI occurs in 0.3-0.
View Article and Find Full Text PDFClin Endosc
August 2025
Department of Gastroenterology, Nara Medical University, Nara, Japan.
Background/aims: This study aimed to compare the stent patency between the novel multi-hole self-expandable metallic stent (MH-SEMS) and conventional partially covered SEMS (PC-SEMS) for malignant distal biliary obstruction (MDBO) in patients with pancreatic carcinoma.
Methods: This retrospective study compared stent patency between patients with MH-SEMS (n=43) and those with PC-SEMS (n=94). Secondary outcomes were overall survival (OS), incidence of recurrent biliary obstruction (RBO), causes of RBO, and adverse events (AEs).